How many insider trades does FilingIQ track for TEVA?

FilingIQ tracks 810 Form 4 insider transactions for TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD), covering filings from Jan 19, 2018 onwards. 115 of those were filed in the last 90 days.

Are TEVA insiders net buyers or net sellers?

Across the full Form 4 history for TEVA, 6 transactions (1%) were open-market purchases and 289 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does TEVA insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is TEVA in?

TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $36.16B.

TEVA insider trading

NYSE Healthcare

TEVA PHARMACEUTICAL INDUSTRIES LTD — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

810

Last 90 days

115

Buys / sells

1% / 36%

Market cap

$36.16B

About TEVA PHARMACEUTICAL INDUSTRIES LTD

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic and other medicines, and biopharmaceutical products in the United States, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products. The company also focuses on the central nervous system (CNS), respiratory, and oncology areas. It provides active pharmaceutical ingredients, as well as contract manufacturing services; and operates an out-licensing platform that offers a portfolio of products to other pharmaceutical companies. The company also offers BENDEKA and TREANDA injections for the treatment of chronic lymphocytic leukemia and indolent b-cell non-hodgkin's lymphoma; COPAXONE to treat patients with relapsing forms of multiple sclerosis; AJOVY for the preventive treatment of migraine in adults; AUSTEDO to treat neurodegenerative and movement disorders chorea associated with Huntington's disease and tardive dyskinesia; UZEDY for the treatment of schizophrenia; ProAir RespiClick inhalation powder; QVAR RediHaler to treat asthma; BRALTUS, a long-acting muscarinic antagonist; CINQAIR/CINQAERO injection; DuoResp Spiromax budesonide and formoterol powder inhaler; and AirDuo RespiClick fluticasone propionate and salmeterol inhalation powder. The company offers its OTC products under the SUDOCREM, NasenDuo, DICLOX FORTE, OLFEN Max, and FLEGAMINA brand names. It has collaboration agreements with MedinCell S.A.; Sanofi; Alvotech; and Biolojic Design Ltd., as well as license agreement with MODAG GmbH. The company was founded in 1901 and is based in Tel Aviv-Yafo, Israel.

Company website: www.tevapharm.com

TEVA insider activity at a glance

FilingIQ has scored 810 insider transactions for TEVA since Jan 19, 2018. The most recent filing in our index is dated May 6, 2026.

Across the full history, 6 open-market purchases and 289 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on TEVA insider trades is 63.2/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live TEVA trades on FilingIQ Raw filings on SEC EDGAR

Latest TEVA Form 4 filings

Daniell Richard EVP, Europe Commercial

S May 5, 2026

Most recent disclosures. Sign up to filter by score, transaction code, or insider role.

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding TEVA

Phoenix Financial Ltd.

$834.16M · 10.2% of AUM

Phoenix Holdings Ltd.

$834.16M · 10.2% of AUM

Lingotto Investment Management LLP

$577.49M · 10.7% of AUM

Rubric Capital Management LP

$193.80M · 7.3% of AUM

MILLER VALUE PARTNERS, LLC

$46.94M · 3.0% of AUM

Frequently asked

How many insider trades does FilingIQ track for TEVA?: FilingIQ tracks 810 Form 4 insider transactions for TEVA (TEVA PHARMACEUTICAL INDUSTRIES LTD), covering filings from Jan 19, 2018 onwards. 115 of those were filed in the last 90 days.
Are TEVA insiders net buyers or net sellers?: Across the full Form 4 history for TEVA, 6 transactions (1%) were open-market purchases and 289 (36%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does TEVA insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is TEVA in?: TEVA PHARMACEUTICAL INDUSTRIES LTD (TEVA) is classified in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a current market capitalisation of $36.16B.

Methodology & sources

Every TEVA insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.